Citi lowered the firm’s price target on Oric Pharmaceuticals (ORIC) to $16 from $17 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORIC:
- Oric Pharmaceuticals reports Q1 EPS (34c), consensus (32c)
- Oric Pharmaceuticals presents Rinzimetostat preclinical data at AACR
- 3 Best Stocks to Buy amid the Market Pullback, According to Top Analysts
- Oric selloff brings attractive entry point, says H.C. Wainwright
- Oric Pharmaceuticals should be bought on selloff, says Citi